Triglyceride Reduction Post-MI Linked to Lower Cardiovascular Risk in SWEDEHEART
Overview
In a study of over 51,000 myocardial infarction (MI) patients from the SWEDEHEART registry, lowering triglycerides by approximately 1.0 mmol/L within one year post-MI was associated with a 14% reduction in major adverse cardiovascular events (MACE). This benefit was most evident in patients with baseline triglyceride levels around 2.2 mmol/L, highlighting the importance of targeting patients with elevated triglycerides for future therapeutic trials.
Background
Despite advances in lipid-lowering therapies, survivors of acute MI remain at high risk for recurrent cardiovascular events. Elevated triglyceride-rich lipoproteins contribute independently to residual cardiovascular risk even when LDL cholesterol is controlled. Previous trials with moderate triglyceride reductions have not demonstrated clear cardiovascular benefits, possibly due to insufficient baseline triglyceride levels or inadequate magnitude of triglyceride lowering. Understanding the relationship between triglyceride changes and cardiovascular outcomes post-MI can guide future trial designs and therapeutic strategies.
Data Highlights
Parameter
Value
Number of MI patients studied
51,719
Median triglycerides at admission
1.4 mmol/L (IQR 1.0–2.0)
Median triglycerides at 1 year
1.2 mmol/L (IQR 0.9–1.6)
Median triglyceride reduction in top quartile
1.0 mmol/L (≥0.6 mmol/L reduction)
Baseline triglycerides in top quartile
2.2 mmol/L (IQR 1.8–2.9)
Follow-up duration
5.6 years
Number of MACE events
9,008
Number of deaths
5,148
Risk reduction for MACE in top quartile
HR 0.85 (95% CI 0.79–0.92)
Risk reduction for all-cause mortality
HR 0.90 (95% CI 0.81–0.99)
Risk reduction for non-fatal MI
HR 0.83 (95% CI 0.74–0.94)
Key Findings
Triglyceride reductions of approximately 1.0 mmol/L within one year post-MI are associated with a 14% lower risk of major adverse cardiovascular events.
Patients achieving the largest triglyceride reductions had the highest baseline triglyceride levels (median 2.2 mmol/L).
The cardiovascular risk reduction was independent of cholesterol-lowering effects from statins, suggesting triglycerides themselves contribute to residual risk.
Only 27% of patients achieved triglyceride reductions of ~1.0 mmol/L, indicating a need to focus on patients with elevated baseline triglycerides for effective intervention.
Current triglyceride-lowering medications that reduce levels by about 25% may be insufficient; therapies achieving 50–70% reductions may be necessary to meaningfully reduce cardiovascular risk.
Clinical Implications
Clinicians should recognize that significant triglyceride lowering post-MI is associated with improved cardiovascular outcomes, particularly in patients with elevated baseline triglycerides (≥2.2 mmol/L). Future therapeutic strategies and clinical trials should prioritize patients with higher triglyceride levels and aim for larger absolute reductions to achieve meaningful cardiovascular risk reduction. Current moderate triglyceride-lowering treatments may not suffice, highlighting the need for more potent agents.
Conclusion
This large real-world study demonstrates that substantial triglyceride reduction after MI correlates with lower cardiovascular risk, especially in patients with elevated baseline triglycerides. These findings support targeting high-triglyceride patients and achieving greater triglyceride lowering in future clinical trials and therapeutic approaches.
References
SWEDEHEART Registry Study 2005-2022 -- Impact of Triglyceride Levels on Major Adverse Cardiovascular Events Post-Myocardial Infarction
